Is Fulgent Genetics Stock a Good Investment?
Fulgent Genetics Investment Advice | FLGT |
- Examine Fulgent Genetics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Fulgent Genetics' leadership team and their track record. Good management can help Fulgent Genetics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Providers & Services space and any emerging trends that could impact Fulgent Genetics' business and its evolving consumer preferences.
- Compare Fulgent Genetics' performance and market position to its competitors. Analyze how Fulgent Genetics is positioned in terms of product offerings, innovation, and market share.
- Check if Fulgent Genetics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Fulgent Genetics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Fulgent Genetics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Fulgent Genetics is a good investment.
Sell | Buy |
Strong Hold
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Fulgent Genetics Stock
Researching Fulgent Genetics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 32.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.46. Some equities with similar Price to Book (P/B) outperform the market in the long run. Fulgent Genetics has Price/Earnings To Growth (PEG) ratio of 1.32. The entity recorded a loss per share of 5.52. The firm had not issued any dividends in recent years.
To determine if Fulgent Genetics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Fulgent Genetics' research are outlined below:
| Fulgent Genetics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 289.21 M. Net Loss for the year was (167.82 M) with profit before overhead, payroll, taxes, and interest of 366.9 M. | |
| About 32.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: Fulgent Genetics Inc Stock Price Up 1.76 percent on Nov 20 |
Fulgent Genetics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Fulgent Genetics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Fulgent Genetics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 3rd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Fulgent Genetics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Fulgent Genetics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2018-11-06 | 2018-09-30 | -0.02 | -0.033 | -0.013 | 65 | ||
2018-08-06 | 2018-06-30 | -0.03 | -0.01 | 0.02 | 66 | ||
2018-05-07 | 2018-03-31 | -0.04 | -0.06 | -0.02 | 50 | ||
2017-05-08 | 2017-03-31 | 0.05 | 0.03 | -0.02 | 40 | ||
2017-02-27 | 2016-12-31 | 0.04 | 0.06 | 0.02 | 50 | ||
2016-11-18 | 2016-09-30 | 0.06 | 0.09 | 0.03 | 50 | ||
2019-05-07 | 2019-03-31 | -0.02 | -0.06 | -0.04 | 200 | ||
2017-11-06 | 2017-09-30 | 0.02 | -0.02 | -0.04 | 200 |
Know Fulgent Genetics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Fulgent Genetics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Fulgent Genetics backward and forwards among themselves. Fulgent Genetics' institutional investor refers to the entity that pools money to purchase Fulgent Genetics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of New York Mellon Corp | 2024-06-30 | 201.2 K | Citadel Advisors Llc | 2024-06-30 | 186.2 K | Amvescap Plc. | 2024-06-30 | 166.7 K | Jpmorgan Chase & Co | 2024-06-30 | 158.6 K | Barclays Plc | 2024-06-30 | 142.6 K | D. E. Shaw & Co Lp | 2024-06-30 | 132.3 K | Bank Of America Corp | 2024-06-30 | 130.7 K | Invenomic Capital Management, Lp | 2024-06-30 | 125.6 K | Bridgeway Capital Management, Llc | 2024-06-30 | 123.6 K | Blackrock Inc | 2024-06-30 | 3.9 M | Vanguard Group Inc | 2024-09-30 | 1.4 M |
Fulgent Genetics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 528.54 M.Market Cap |
|
Fulgent Genetics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.16) | (0.16) | |
| Return On Capital Employed | (0.06) | (0.07) | |
| Return On Assets | (0.14) | (0.14) | |
| Return On Equity | (0.15) | (0.16) |
Determining Fulgent Genetics' profitability involves analyzing its financial statements and using various financial metrics to determine if Fulgent Genetics is a good buy. For example, gross profit margin measures Fulgent Genetics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Fulgent Genetics' profitability and make more informed investment decisions.
Fulgent Genetics' Earnings Breakdown by Geography
Please note, the imprecision that can be found in Fulgent Genetics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Fulgent Genetics. Check Fulgent Genetics' Beneish M Score to see the likelihood of Fulgent Genetics' management manipulating its earnings.
Evaluate Fulgent Genetics' management efficiency
Fulgent Genetics has return on total asset (ROA) of (0.0415) % which means that it has lost $0.0415 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1435) %, meaning that it created substantial loss on money invested by shareholders. Fulgent Genetics' management efficiency ratios could be used to measure how well Fulgent Genetics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.16 in 2024. Return On Capital Employed is likely to drop to -0.07 in 2024. At this time, Fulgent Genetics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 30.5 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 49.4 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 38.05 | 39.95 | |
| Tangible Book Value Per Share | 32.51 | 34.13 | |
| Enterprise Value Over EBITDA | (16.73) | (15.89) | |
| Price Book Value Ratio | 0.76 | 0.72 | |
| Enterprise Value Multiple | (16.73) | (15.89) | |
| Price Fair Value | 0.76 | 0.72 |
At Fulgent Genetics, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Beta 1.508 |
Basic technical analysis of Fulgent Stock
As of the 22nd of November, Fulgent Genetics shows the Standard Deviation of 2.59, variance of 6.72, and Mean Deviation of 1.99. Fulgent Genetics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Fulgent Genetics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Fulgent Genetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Fulgent Genetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Fulgent Genetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Fulgent Genetics' Outstanding Corporate Bonds
Fulgent Genetics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Fulgent Genetics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Fulgent bonds can be classified according to their maturity, which is the date when Fulgent Genetics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| US359678AC31 Corp BondUS359678AC31 | View | |
| HB Fuller 4 Corp BondUS359694AB24 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand Fulgent Genetics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Fulgent Genetics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (0.53) | |||
| Mean Deviation | 1.99 | |||
| Coefficient Of Variation | (613.53) | |||
| Standard Deviation | 2.59 | |||
| Variance | 6.72 | |||
| Information Ratio | (0.20) | |||
| Jensen Alpha | (0.50) | |||
| Total Risk Alpha | (0.73) | |||
| Treynor Ratio | (0.54) | |||
| Maximum Drawdown | 17.58 | |||
| Value At Risk | (3.86) | |||
| Potential Upside | 2.95 | |||
| Skewness | (1.09) | |||
| Kurtosis | 4.41 |
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (0.53) | |||
| Mean Deviation | 1.99 | |||
| Coefficient Of Variation | (613.53) | |||
| Standard Deviation | 2.59 | |||
| Variance | 6.72 | |||
| Information Ratio | (0.20) | |||
| Jensen Alpha | (0.50) | |||
| Total Risk Alpha | (0.73) | |||
| Treynor Ratio | (0.54) | |||
| Maximum Drawdown | 17.58 | |||
| Value At Risk | (3.86) | |||
| Potential Upside | 2.95 | |||
| Skewness | (1.09) | |||
| Kurtosis | 4.41 |
Consider Fulgent Genetics' intraday indicators
Fulgent Genetics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Fulgent Genetics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 11608.23 | |||
| Daily Balance Of Power | (0.42) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 17.32 | |||
| Day Typical Price | 17.19 | |||
| Price Action Indicator | (0.53) | |||
| Period Momentum Indicator | (0.33) | |||
| Relative Strength Index | 34.18 |
Fulgent Genetics Corporate Filings
8K | 8th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 5th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 27th of March 2024 Other Reports | ViewVerify |
Fulgent Stock media impact
Far too much social signal, news, headlines, and media speculation about Fulgent Genetics that are available to investors today. That information is available publicly through Fulgent media outlets and privately through word of mouth or via Fulgent internal channels. However, regardless of the origin, that massive amount of Fulgent data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Fulgent Genetics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Fulgent Genetics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Fulgent Genetics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Fulgent Genetics alpha.
Fulgent Genetics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Fulgent Genetics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Fulgent Genetics Corporate Management
| Doreen Ng | VP Office | Profile | |
| DABMG FACMG | Chief Director | Profile | |
| Paul Kim | Chief Officer | Profile | |
| Natalie Prescott | General Officer | Profile | |
| Lawrence MD | Chief Officer | Profile |
Additional Tools for Fulgent Stock Analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.